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Abstract A study was carried out to evaluate efficacy of
Macroplastique® (MPQ) Implantation System (MIS) in
women with urodynamic stress urinary incontinence (SUI)
and urethral hypermobility after an unsuccessful conserva-
tive treatment. This is a prospective randomized controlled
trial in women without previous incontinence surgery.
Twenty-four women received MPQ. Twenty-one controls
underwent a pelvic floor muscle exercises home program.
Follow-up was at 3 months and the MPQ group also at
12 months. At 3 months, pad usage decreased significantly
more in the MPQ group than in the control group (p=
0.015). According to physician and patient self-assessment,
respectively, 71% and 63% women in the MPQ group were
considered cured or markedly improved. This was signif-
icantly higher compared to controls. There was a significant
higher increase of Incontinence Quality-of-Life question-
naire score in the MPQ group compared to controls (p=
0.017). Improvements in MPQ group at 3 months are
sustained to 12 months. Adverse events were mild and
transient. MIS is an acceptable option for women with SUI
and urethral hypermobility.
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Introduction
For the treatment of stress urinary incontinence (SUI) in
adult women, there is a broad variety of therapies
nowadays. They range from physiotherapy to surgical
interventions. Injection therapy with urethral bulking agents
is generally considered as a minimally invasive procedure
for SUI [1]. However “minimally invasive” is a relative
term and can be viewed as minimally invasive from the
surgeon’s perspective or the patient’s. Acceptance for
injection therapy as the least invasive of all surgical
procedures is progressing [2, 3].
Injection therapy can be used for all types of SUI.
Urethral hypermobility is thought to decrease the success of
treatment with injectables [4]. However, published results
of periurethral collagen injections for SUI caused by
hypermobility indicate positive outcome [5]. No differences
in success rates with and without hypermobility were
reported [6].
Macroplastique® is a urethral bulking agent that has
been used in the treatment of urodynamic stress inconti-
nence (USI) in adult women for approximately 9 years [2,
7, 8]. In studies, success rates vary from 58% (long term) to
73% (short term) [9]. Macroplastique® is a bulking agent
that consists of solid polydimethylsiloxane particles with a
mean maximum diameter of 209 μm [10]. After injection,
these particles seem to be nonmigratory and will be
organized within 6 to 8 weeks in firm nodules with
infiltrated collagen and surrounded by a fibrous sheath that
is well developed at 9 months [11–14].
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The aim of this study is to evaluate the efficacy and the
quality of life in women using the Macroplastique®
Implantation System (MIS), a novel guiding instrument
for transurethral injection of Macroplastique®, as a mini-
mally invasive procedure in adult women with USI and
urethral hypermobility after an unsuccessful conservative
treatment (i.e., no improvement of SUI after pelvic floor
muscle exercises (PFME)).
Materials and methods
The study was approved by the Medical Ethical Committee
of the University Hospital Maastricht, the Netherlands.
Data out of this study and the informed consent forms were
obtained complying with the applicable regulatory require-
ments, adhering to Good Clinical Practice and to the ethical
principles that have their origin in the Declaration of
Helsinki [15]. The study is designed to comply with the
CONSORT statement and follows the CONSORT checklist
registration study (www.consort-statement.org)
Forty-seven adult women with USI and urethral hyper-
mobility after an unsuccessful conservative treatment and
no history of previous incontinence surgery were included
in this prospective, randomized, controlled and single-
center clinical trial between April 2002 and May 2007.
Prior to participation of this study, each woman completed
dipstick urinalysis, a Quality-of-Life Questionnaire (QoL),
Patient Questionnaire including Stamey incontinence rating
[16]. Stamey rating is as follows. Grade 0: The patient is
continent (dry). Grade 1: The patient will lose urine with
sudden increases in abdominal pressure (stressful activities
such as lifting weights, coughing, or sneezing) but never in
bed at night. Grade 2: The patient’s incontinence worsens
with lesser degrees of stress such as walking, standing erect
from a sitting position, or sitting up in bed. Grade 3: The
patient has total incontinence and urine is lost with any
activity, irrespective of position. Also, a frequency–volume
chart (FVC) and 1-h International Continence Society pad
test [17] in addition to routine urogynecological workup
including detailed physical examination with assessment of
bladder neck excursion measurement and pelvic organ
prolapse [18] and urodynamic assessment were performed.
The Incontinence Quality-of-Life (I-QoL) Questionnaire
was used in this study for the assessment of QoL [19]. The
Dutch-translated and validated version is a reliable instru-
ment for the assessment of QoL in women with urinary
incontinence. The mean score lies theoretically between 1
and 5 and, the higher the score is, the more satisfied
patients are about their continence condition. The 22 I-QoL
item scores can be divided in three domains: “avoidance
and limiting behavior,” “psychosocial impacts,” and “social
embarrassment”. Measurement of bladder neck mobility
was assessed by the Q-tip test [20]. Independently, Valsalva
leak point pressure was measured. This measurement
provides a validated tool to assess urethral function allowing
an estimation of the relative contributions of intrinsic
sphincter deficiency and urethral hypermobility [21].
Women, who met the primary inclusion and exclusion
criteria (Table 1), were considered candidates for random-
ization. Written informed consent was obtained from all
women. The women were randomized for Macroplastique®
injection utilizing the Macroplastique® Implantation Device
(MID) or a control PFME home training program. Random-
ization process was performed using sealed envelopes
containing the treatment assignment. A table of random
numbers was used; all 0–4 were assigned toMPQ and all 5–9
were assigned to control PFME home training program. The
control group was offered written instruction material for
the maintenance of the PFME home training program.
The transurethral injection was performed using the
MIS. The MIS consists of a set of two syringes of
Macroplastique® (2.5 ml each), the implantation device
(MID), and two special needles. The MID is used to
standardize the location of periurethral injection, as de-
scribed by Henalla et al. [22]. The initial injection was
placed 10 mm from the bladder neck. The procedure was
performed under sterile conditions and was carried out
under local anesthesia in day case setting. Although only
women with negative urinalysis and urine culture were
allowed to undergo the intervention, postoperatively,
250 mg ciproxin twice daily was given for 5 days as
prophylaxis. If the patient was unable to pass urine
spontaneously up to 3 or 4 h following the procedure,
“in and out catheterization” with a catheter Ch12 was
performed to relieve any symptoms of urinary retention.
If residuals of more than 100 ml were detected, the
patient was instructed to perform clean intermittent self-
catheterization (CISC) with a catheter Ch12.
Both patient groups were followed up to 3 months from
the moment of injection and the Macroplastique® group
also up to 12 months after treatment. The 3- and 12-month
follow-up visit included an FVC, I-QoL Questionnaire,
Patient Questionnaire, and a pad test. A further Macro-
plastique® implantation procedure was scheduled after the
3-month follow-up, if clinically indicated or requested by
the patient. A reimplantation was performed at a new level,
in the midurethral position as defined by location with the
MID. After repeat Macroplastique® implantation, women
were again followed up at 3 and 12 months. Objective
assessments of treatment outcome are the results of pad
testing and FVC. Subjective assessments of treatment
outcome are the results of I-QoL Questionnaire with
Stamey incontinence rating, side effects, and complications,
investigator Stamey incontinence rating, and subjective
investigator stress incontinence cure rating. Treatment
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success and failure are defined as follows: success is
“cured” (dry) or “markedly improved” (no further inconti-
nence treatment needed), and failure is “slightly improved”
(requires further incontinence treatment) or “unchanged”
(requires further incontinence treatment).
Statistical analysis
The sample size was determined using the following power
calculation. Given p1=30% (success rate of control), p2=
75% (success rate of Macroplastique®), α=0.05, and β=
0.05 results in a value of 25.5 for n. The number of patients
of each group should be a least 26. Metric variables are first
inspected for normality of statistical distribution by the
Kolmogorov–Smirnov test. If normally distributed, means
and standard deviations are given for univariate variables; if
not, medians and ranges are also provided. Categorical data
are represented by frequencies and percentages (or propor-
tions). Patient demographical characteristics and clinical
data are broken down for the randomization arm (Table 2):
Macroplastique® group or control group. For normally
distributed variables, Student t test is used to verify
similarity of means for baseline characteristics; for non-
normally distributed variables, the Mann–Whitney test is
used. For categorical data, the log-likelihood chi-squared test
is applied. For the pad test on the data, a 10-log transforma-
tion is also done to ensure normality of distribution for the
performance of Student t test. The analysis of I-QOL data is
performed at two levels: first, a general total scale is
calculated on all 22 items and next the three subscales (the
avoidance and limiting behavior, psychosocial impacts, and
social embarrassment items) are constructed. To test
changes in I-QoL data at 3 months after baseline measure-
ments, repeated-measures analysis of variance is done and
to control these changes for baseline factors or variables
repeated-measures analysis of covariance is performed. To
control for baseline measurements (and other confounding
variables or factors) in nonnormally distributed changes in
outcome variables measured at 3 months, a Mann–Whitney
test is performed on the Studentized residuals of these
outcomes found in regression analysis.
According to intention-to-treat principles in data analy-
sis, missing values are imputed by general mean substitu-
tion. A p value of less than 0.05 is considered to be
statistically significant. All data were analyzed with SPSS-
pc, version 15.0 [23].
Results
The MPQ group contained 24 women and the control group
21. Two patients had to be excluded because they did not
Table 1 Inclusion and exclusion criteria
Inclusion
Female and at least 18 years of age
Urodynamic stress urinary incontinence and urethral hypermobility
Urodynamic assessment of SUI and VLPP >60-cm water
SUI did not show defined improvement after PFME therapy
No more than stage 0, 1, or 2 pelvic organ prolapse (Bump classification)
Negative dipstick urinalysis
Postvoid residual urine ≤100 ml
Not pregnant or within 12 months postpartum
Understanding of the Dutch language
Written informed consent document
Exclusion
Any prior solid particle UBA treatment or any surgical anti-incontinence procedure
A form of urinary incontinence other than SUI contributing substantially to their symptoms
A neurogenic bladder
Urinary incontinence due to an anatomical defect, fibrotic urethral mucosa (preventing Macroplastique® bolus formation),
tissue damage due to injury, pelvic radiotherapy, or other therapy affecting the bladder neck and/or urethral tissues
A history of intermittent or long-term use of intraurethral continence devices
Voiding difficulties
A history of unexplained hematuria
Cystitis, urethritis, or evidence of possible infection, which would preclude safe penetration of the urethral wall with the implantation needle
An incurable malignant disease or other form of disease that is advancing rapidly and causing deterioration of the patient’s physical condition
Any condition that could lead to serious postoperative complications (e.g., current infection or uncontrolled diabetes)
Lactating within 12 months postpartum or planning to become pregnant in the next 12 months
Morbidly obese (i.e., body mass index; BMI>40 kg/m2)
Unable or unwilling to perform clean intermittent self-catheterization if the need arises (e.g., lack of manual dexterity, arthritic hands,
dementia, etc.)
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fulfill inclusion criteria (one was accidentally included
twice and one had mainly frequency and urgency com-
plaints). Mean age was 55 years (range 40–76). Baseline
characteristics of both groups were similar as shown in
Table 1. The injected volume of MPQ was 5 ml in all
women. An additional injection of 5 ml MPQ was
performed in two women after the 3-month follow-up.
The treatment was well tolerated according to the women
treated and considered acceptable and easy to perform by
the physician. The following adverse events of 26 transure-
thral Macroplastique® injection using Macroplastique®
Injection System in 24 women were reported: retention 19
(73.1%)*, mild pain 2 (7.7%), hematuria 2 (7.7%), dysuria
12 (46.2%), leakage implant 2 (7.7%), infection 0 (0%).
Duration of retention (>100 ml) and dysuria complaints was
1–2 days, except in one woman with persistent retentions
because of a “de novo” prolapse of the anterior vagina wall.
The women experienced these events as acceptable and
mild. Product-related side effects were not seen. There were
no dropouts at the 3-month follow-up (Fig. 1).
The mean pad test at baseline showed a 19.6-g (median
7.5, range 0–115) and 24.9-g (median 13.8, range 2–84)
urinary loss in the control group and MPQ group,
respectively. After 3 months, the mean pad test showed an
11.9-g (median 4, range 0–66.6) and 15.1-g (median 3,
range 0–133) urinary loss in the control group and MPQ
group, respectively. This improvement was not statistically
significant between the two groups (p=0.328).
The mean number of pads used per day at baseline was
2.7 (median 3, range 0–6) and 3.4 (median 3, range 0–6) in
the control group and MPQ group, respectively. After
3 months, the mean number of pads were 2.5 (median 2,
range 0–6) and 1.9 (median 1, range 0–11) in the control
group and MPQ group, respectively. The number of pads
used at 3 months in the MPQ group decreased statistically
significantly compared the number used in the control
group (p=0.015).
After the 3-month follow-up, five women in the MPQ
group received other continence treatment because of
treatment failure. The incontinence condition of women
was rated by Stamey rating. At baseline and 3-month
follow-up, the frequencies in grading for both groups as
well as the 12-month follow-up of the MPQ group are
shown in Table 3. At 3-months follow-up, the Stamey
grading showed a statistically significant difference com-
pared to baseline scores (p=0.020).
The physician’s global impression of the incontinence
condition of women was rated by the final surgeon
incontinence rating (Table 4). The number of women (17;
70.8%) that was “cured” or “markedly improved” at
3 months was statistically significantly higher than that in
the control group (6; 28.5%; p=0.029).
The subject’s global impression of the incontinence
condition was rated by patient self-assessment of the
incontinence problem and is presented in Table 4. There
was a statistically significant difference in the number of
women (15; 62.5%) “cured” or “markedly improved” at
3 months in the MPQ group compared to that in the control
group (4; 19.0%; p=0.002).
The Dutch-validated overall 22-item I-QoL showed a
mean total score at baseline for the control group and MPQ
group of 2.96 (SD=0.62) and 2.59 (SD=0.61), respectively,
and at 3 months this mean total score was 3.03 (SD=0.66)
and 3.20 (SD=0.73), respectively (Table 5). The increase in
the MPQ group was significantly higher compared to the
control group (F ratio=9.83:1 and 43 df, p=0.003). When
the I-QoL scores are corrected for baseline values, the
difference remained statistically significant (F ratio=6.15:1
and 42 df, p=0.017). The mean scores and standard
deviations of the domain scales are also shown in Table 5.
In all three scales and controlled for their respective
baseline measurements, there was a statistically significant
improvement in the means of the MPQ group compared to
the ones of the control group (F=4.57:1 and 42 df, p=
0.038, F=4.85:1 and 42 df, p=0.033, F=7.99:1 and 42 df,
p=0.007, respectively). The increase in mean scores was
the highest on the “social embarrassment” subscale after
correction for possible differences in baseline values
between the control and MPQ group. In contrast to the
control group, the I-QoL for the MPQ group was again
measured at 12 months after treatment. If—outside the trial
data analysis—a cohort trend analysis for just these 18
Table 2 Patient’s characteristics
MPQ group (n=24) Control group (n=21) p value
Mean age, years (SD; range) 54.7 (8.9; 41–76) 55.6 (8.9; 40–73) 0.73
Mean BMI, kg/m2 (SD; range) 26.6 (4.3; 20–40) 28.3 (8.3; 19–38) 0.41
Menstrual cycle (normal/perimeno/meno) 6/3/15 7/2/12 0.81a
Parities (median) 2 2 0.23a
Duration of incontinence, months (range) 142 (36–360) 118 (36–360) 0.35
VLPP, cm water (SD; range) 102 (28; 70–172) 93 (21; 63–136) 0.28
SD standard deviation
a Log-likelihood chi-squared test (other p values: Student’s t test)
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patients who had a successful MPQ treatment at 3 months
is done, the improved mean overall and subscale scores in
I-QoL at 3 months turns out to be sustained to the 1-year
follow-up. The overall score and the subscale score social
embarrassment seem even to improve statistically signifi-
cant compared to the 3-month scores (F=4.87:1 and 17 df,
p=0.041, F=7.77:1 and 17 df, p=0.013, respectively;
Table 5).
At 12 months, physician and patient self-assessment
“cure” and “markedly improved” rate was 88.9% (16/18)
and 82.4% (14/17) in the MPQ group, respectively (Table 4).
After treatment, five women presented with symptoms of
de novo urgency but only one needed medical treatment.
Discussion
To our knowledge, this is the first randomized clinical trial
comparing transurethral Macroplastique® injection with a
control pelvic floor muscle exercise home training program
in adult women with urodynamic SUI and urethral
hypermobility after an unsuccessful conservative treatment.
The enrollment time was long (5 years); this could be due
to the strict inclusion and exclusion criteria. Also, in this
period of time, the suburethral slings became popular and
could have been of influence on the patient’s choice of
treatment.
The exact mechanism of achieving continence with
urethral bulking agents is unknown. It is commonly thought
that they increase urethral resistance at the level of the
bladder neck by adding “bulk” or provide internal support
to the urethral mucosa and creating urethral coaptation
when injected submucosally [14].
At 3 months, results of the pad test results showed
improvement, although no significant difference between
the two groups could be shown. We have used the 1-h pad
test as recommended by the International Continence
Society [17]. However, a number of studies have reported
poor reproducibility for the 1- and 24-h pad test [24–27]. In
a study by Simons et al., the test–retest reliability of the
1-h pad test was shown to be inadequate, with the first
and second tests differing by −44 to +66 g, despite the
women having similar bladder volumes [27]. Lower
anxiety levels at the second test may account for this
finding. The 1-h pad test is a useful baseline measure of
incontinence, but the poor repeatability suggests that is not
an optimal measure of posttreatment.
More clearly, the decrease in number of pads used in the
MPQ group at 3 months was significantly different from the
control group. Also, the subjective parameters were
significantly better in the MPQ group compared to the
Fig. 1 Flow diagram of study
Table 3 Stamey rating frequencies (n) for the control and the MPQ
group at baseline and at 3-month follow-up and at 12 months for the
successful part of the MPQ group only
Grade 0 I II III p value
Baseline Control (n=21) 0 14 7 0
MPQ (n=24) 1 15 8 0
3 months Control (n=21) 1 16 4 0
MPQ (n=24) 8 15 1 0 0.020
12 months MPQ (n=18) 10 7 1 0
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control group. The “cure” and “markedly improved” rates
were sustained in the MPQ group at 12 months. These
results of MPQ treatment of SUI in patients with urethral
hypermobility are in line with data from literature in
patients without hypermobility [28]. Comparing the results
with other more invasive surgical treatments, the MPQ
shows a slightly lower success rate, however, with a lower
risk of complications [29]. In this study, the retention rate
seems rather high. This can be explained by strict control of
women after the procedure. The duration of retention was 1
to 2 days and treated by CISC, except in one woman with a
body mass index of 40 kg/m2, who had persistent retention
because of a “de novo” prolapse of the anterior vagina wall
unrelated to the procedure. Surgical correction of this
prolapse was necessary. CISC may influence the results of
injection therapy by possible dislocation and/or loss of the
bulking agent. However, a small-sized catheter (Ch 12) was
used to minimalize this risk as much as possible. The
improvement in the quality of life is in the same range as
with surgical interventions and confirms the trend in
patient’s preference to have a procedure with a lower risk
of complications [30]. In a recent study of Robinson et al.,
the majority of women have realistic expectations regarding
outcome hoping for improvement so that their quality of
life increases. In general, they are able to tolerate the
inconvenience of minor lower urinary tract symptoms.
Women would appear to prefer a minor procedure with a
lower risk of complications and are content to accept a
lower success rate [30].
An advantage of Macroplastique® implantation using the
MID is that it is performed following an outpatient
treatment protocol requiring local anesthesia only. Also,
the instrument is easy to handle in comparison to the
cystoscope, with predetermined and consistent depth of
Table 4 Final surgeon’s subjective cure rating and the patient self-assessment of patient’s incontinence condition (n) for the control and the MPQ
group at 3-month follow-up and at 12 months for the successful part of the MPQ group only










Control 3 months 21 2 4 4 11 21 0 4 3 14
MPQ 3 months 24 8 9 1 6 0.029 24 7 8 2 7 0.002
MPQ 12 months 18 9 7 1 1 17a 6 8 2 1
a One missing data
Table 5 (A) Mean (sub)scale scores and standard deviations (SD) of
the I-QoL at baseline and 3 months for both treatment groups (overall
mean imputed data; n=45). Scores will lie between 1.00 (worst
possible QoL) and 5.00 (best possible QoL). (B) Mean (sub)scale
scores and standard deviations (SD) of the I-Qol at baseline and at 3
and 12 months for patients who had a successful MPQ treatment after
3 months (n=18). Scores will lie between 1.00 (worst possible QoL)
and 5.00 (best possible QoL)
Subscale Treatment Number Baseline 3 months 12 months p value p value controlled for baseline values
A
Overall Control 21 2.96 (0.62) 3.03 (0.66)
MPQ 24 2.59 (0.61) 3.20 (0.73) 0.003a 0.017c
Avoidance and limiting behavior Control 21 2.86 (0.72) 2.99 (0.71)
MPQ 24 2.55 (0.65) 3.26 (0.86) 0.012a 0.038c
Psychosocial impacts Control 21 3.27 (0.66) 3.31 (0.65)
MPQ 24 2.76 (0.70) 3.37 (0.74) 0.003a 0.033c
Social embarrassment Control 21 2.53 (0.66) 2.59 (0.87)
MPQ 24 2.31 (0.68) 2.95 (0.81) 0.004a 0.007c
B
Overall 18 2.58 (0.64) 3.38 (0.70) 3.85 (0.81) 0.041b 0.006d
Avoidance and limiting behavior 18 2.47 (0.58) 3.37 (0.80) 3.65 (0.73) 0.185b 0.093d
Psychosocial impacts 18 2.76 (0.77) 3.60 (0.66) 3.94 (0.78) 0.157b 0.058d
Social embarrassment 18 2.35 (0.71) 3.13 (0.73) 3.77 (0.97) 0.013b 0.008d
a ANOVA results (time × group) effects
b Paired t test
c ANCOVA results (time × group) effects
dWilcoxon paired test
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needle penetration and consistent implant placement at
three predetermined locations.
Conclusions
In the treatment algorithm of stress urinary incontinence,
the bulking agent Macroplastique® using MPQ Implanta-
tion Device seems to be a suitable option as a first-line
surgical treatment. The procedure is easy to perform, safe,
and well accepted by women and physician. The success
rates are satisfactory and the patient’s quality of life
increases significantly. The results appear to be sustained
at least for 1 year postoperatively.
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